0.60Open0.45Pre Close255 Volume1.10K Open Interest5.00Strike Price13.03KTurnover256.60%IV11.70%PremiumNov 15, 2024Expiry Date0.30Intrinsic Value100Multiplier18DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type-0.4269Delta0.1448Gamma3.76Leverage Ratio-0.0289Theta-0.0015Rho-1.61Eff Leverage0.0041Vega
Revance Therapeutics Stock Discussion
On October 24, 2024, Revance Therapeutics, Inc. (the “Company”) and Teoxane SA (“Teoxane”), entered into the Sixth Amendment to the Exclusive Distribution Agreement (the “Sixth Amendment”). As previously disclosed on a Current Report on Form 8-K filed on January 10, 2020, the Company entered into the Exclusive Distribution Agreement with Teoxane on January 10, 2020 (the “Distribution Agreement”), pursuant to which Teoxane granted the Company with the exclus...
🟢 Recently Announced:
⇒ $Organon & Co (OGN.US)$ to acquire Dermavant
⇒ $Rafael Holdings (RFL.US)$ to acquire Cyclo Tx
⇒Crown Lab to acquire $Revance Therapeutics (RVNC.US)$
⇒ $Recursion Pharmaceuticals (RXRX.US)$ merger with Exscientia
🔴 Recently Closed:
⇒ $Johnson & Johnson (JNJ.US)$ acquired V-Wave
⇒ Pharmacosmos acquired $GTHX
What companies will be next? 🤔
Crown Laboratories and Revance Announce Entry Into Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced a merger agreement, with Crown offering to acquire all outstanding Revance shares for $6.66 per share in cash. This represents a total enterprise value of $924 million and a 89% premium over Revance's closing price on August 9, 2024. The merger aims to create a leading, innovative aesthetics and skincare company, combini...
No comment yet